Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Merck Fosamax Distribution Deal With CVS ProCare Draws Protest From NCPA

  • News

Executive Summary

The National Community Pharmacists Association is questioning the clinical necessity of limiting distribution of the 40 mg dose of Merck's Fosamax for Paget's disease to CVS ProCare.

You may also be interested in...



Medicare Rx Benefit Could Lead To Tightened Pediatric Exclusivity - CVS CEO

Congress will likely tighten the pediatric exclusivity incentive as it considers a Medicare drug benefit, CVS CEO Tom Ryan predicted during an earnings call.

Medicare Rx Benefit Could Lead To Tightened Pediatric Exclusivity - CVS CEO

Congress will likely tighten the pediatric exclusivity incentive as it considers a Medicare drug benefit, CVS CEO Tom Ryan predicted during an earnings call.

Merck Fosamax 40 mg Distribution Plan Leaves Room For Once-Weekly Agent

Merck's exclusive distribution program for patients receiving Fosamax 40 mg tablets for Paget's disease will give the company pricing flexibility when a once-weekly 35 mg formulation is approved for prevention of osteoporosis.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS036473

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By